Potentially, non‐responders to anti‐VEGF therapy could benefit from this treatment paradigm, since a genetic variation of Nrp1 is an indicator of reduced treatment response to anti‐VEGF therapeutics like Ranibizumab in patients with NV AMD (Lores‐Motta et al,2016; Lores‐Motta et al,2018). This evidence concerns the gene VEGFA and age-related macular degeneration.